BenevolentAI announced that AstraZeneca has added a novel target for Heart Failure to its discovery portfolio through its collaboration with BenevolentAI. Novel target for Heart Failure was discovered using BenevolentAI?s AI-drug discovery platform and experimentally validated by AstraZeneca First target to be selected from the extended collaboration with AstraZeneca, highlighting continued positive progress in the field of Target Identification BenevolentAI?s strategic collaboration with AstraZeneca began in 2019, and originally focused on discovering potential new treatments for idiopathic pulmonary fibrosis (IPF) and chronic kidney disease (CKD). The collaboration was expanded in January 2022 to two new disease areas, Heart Failure and Systemic Lupus Erythematosus (SLE), demonstrating how the Benevolent Platform?

can be applied across multiple therapeutic areas. The innovative collaboration structure sees scientists and technologists from the two companies work side-by-side, combining BenevolentAI?s AI-driven drug discovery platform and biomedical knowledge with AstraZeneca?s scientific and disease specific expertise, leading to novel and robust Target Identification. Both the initial and extended collaboration were agreed on similar terms with upfront payments on signing, research funding alongside discovery, development and commercial milestones.

Additionally, the Company will receive tiered royalties on net sales of any commercialised products. Heart Failure is a complex syndrome which occurs when the heart cannot pump enough blood around the body. It is often complicated by multiple interrelated diseases, so requires a deep understanding of the potential disease drivers in individual patients.

Current heart failure treatments follow a ?one-size-fits-all? approach. However, due to the wide range of mechanisms by which heart failure can occur, there remains an unmet need for new therapies as up to 50% of patients die within five years of diagnosis.